Method of Treating Cancer
Methods for treating cancer are provided including administering a patient needing treatment a therapeutically effective amount of one or more antioxidants selected from the group of catalase, N-acetylcysteine, glutathione peroxidase, salen-transition metal complexes, dicumarol, and derivatives thereof.
1 . A method for treating cancer in a patient, comprising administering to the patient a therapeutically effective amount of dicumarol or analog thereof and a vitamin K or analog thereof.
2 . The method of claim 1 , wherein an analog of dicumarol is administered, the analog being selected from the group consisting of phenprocoumon (4-hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one), warfarin (3-(α-acetonylbenzyl)-4-hydroxycoumarin), 7-[Diethylamino]-4-trifluoromethylcoumarin, 7-amino-4-trifluoromethylcoumarin, 7-amino-4-methylcoumarin, 4-methylcoumarin, 7-hydroxy-4-methylcoumarin, 7,8-dihydroxy-4-methylcoumarin, and 1,1-dimethyl-alloylcoumarin, and derivatives and analogs thereof.
3 . The method of claim 1 , wherein the vitamin K or analog thereof is selected from the group consisting of phylloquinone (vitamin K 1 ), menaquinone (vitamin K 2 ), menadione (vitamin K 3 ), vitamin K 5 , dihydrovitamin K, menaquinone-4, and derivatives and analogs thereof
4 . The method of claim 1 , wherein the cancer is selected from the group consisting of carcinomas, myelomas, melanomas, and lymphomas.
5 . The method of claim 1 , wherein the cancer is selected from the group consisting of melanoma, non-small cell lung cancer, small cell lung cancer, renal cancer, colorectal cancer, breast cancer, pancreatic cancer, gastric cancer, bladder cancer, ovarian cancer, uterine cancer, lymphoma, and prostate cancer.
6 . The method of claim 1 , wherein the cancer is selected form the group consisting of melanoma, lung cancer, breast cancer, and prostate carcinoma.
7 . The method of claim 1 , wherein the dicumarol or analog thereof and the vitamin K or analog thereof are administered simultaneously in the same or separate pharmaceutical preparations.
8 . The method of claim 1 , wherein the dicumarol or analog thereof and the vitamin K or analog thereof are administered in equimolar concentration.
9 . The method of claim 1 , wherein the dicumarol or analog thereof and the vitamin K or analog thereof are administered in a pharmaceutically acceptable carrier.
10 . The method of claim 1 , wherein the dicumarol or analog thereof and the vitamin K or analog thereof are administered via a route selected from the group consisting of parenteral, intravenous, oral, intradermal, subcutaneous, and topical administration.
11 . The method of claim 1 , wherein the dicumarol or analog thereof is administered in an amount of about 0.1 mg to about 5000 mg per day.
12 . The method of claim 1 , wherein the dicumarol or analog thereof is administered in an amount of about 10 mg to about 1000 mg per day.
13 . The method of claim 1 , wherein the vitamin K or analog thereof is administered in an amount of about 0.1 mg to about 500 mg per day.
14 . The method of claim 1 , wherein the vitamin K or analog thereof is administered in an amount of about 0.5 mg to about 200 mg per day.
15 . The method of claim 1 , further comprising administering to the patient another anticancer agent.
16 . The method of claim 15 , wherein the anticancer agent is selected from group consisting of cisplatin, carboplatin, cyclophosphamide, nitrosoureas, fotemustine, herceptin, carmustine, vindesine, etoposide, daunorubicin, adriamycin, taxol, taxotere, fluorouracil, methotrexate, melphalan, bleomycin, salicylates, aspirin, piroxicam, ibuprofen, indomethacin, maprosyn, diclofenac, tolmetin, ketoprofen, nabumetone, oxaprozin, doxorubicin, nonselective cyclooxygenase inhibitors, and selective cyclooxygenase-2 (COX-2) inhibitors.
17 . A method for treating a cancer selected from the group consisting of carcinomas, myelomas, melanomas, and lymphomas in a patient, comprising administering to the patient dicumarol in an amount effective to suppress NAD(P)H:quinnone oxidoreductase activity and inhibit constitutive activation of NF-κB in cancer cells, and administering a vitamin K in an amount effective to offset the anticoagulant effect of dicumarol.
18 . The method of claim 17 , further comprising administering to the patient another anticancer agent.
19 . The method of claim 18 , wherein the anticancer agent is selected from the group consisting of cisplatin, cyclophosphamide, etoposide, duanorubicin, adriamycin, fluorouracil, and carboplatin.
20 . The method of claim 17 , wherein the dicumarol is administered in an amount of about 10 mg to about 1000 mg per day and the vitamin K is administered in an amount of about 0.5 mg to about 200 mg per day.